⏰ Launch Offer Ends
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Investival Showcase - GMT (Greenwich Mean Time, GMTZ)
2025 has been a year of economic uncertainty amid a changing geopolitical and macroeconomic stress. Our panel of investment experts discuss how Europe is responding to the global challenges and how we can make Europe a fertile ground for innovation.
Europe’s current state, opportunities, strengths and challenges
Addressing the persisting early-stage funding gaps and how to meet the high bar for financing
China as a rising force – how does Europe & US compare?
The Impact of AI and digital health on investment patterns across regions
Strategies for European companies to attract global investment
- Janke Dittmer - General Partner, Gilde Healthcare
- Tim Haines - Executive Partner, Abingworth
- Regina Hodits - Managing Director, Angelini Ventures
- Maina Bhaman - Partner, Sofinnova Partners
The US has long been considered the place to be in the life sciences space given the market size and more attractive investment and reimbursement landscapes. Join US market access experts as they discuss the changing US political landscape and how to find success across the pond.
Accessing US capital markets
Strategic partnerships with American investors
The importance of having US based stakeholders and how to lead a transatlantic team
Navigating FDA requirements for European companies
- Tom Capon - Principal, Optum Ventures
- Gautam Kainth - Partner, TCP Health Ventures
- Max Klement - Principal, Novo Holdings
The past 18 months have seen a shift in life sciences M&A, with fewer deals at higher values being completed. Here experts will explore the reasons for the shift and how to best position your company for a fair and efficient acquisition.
Latest M&A trends in life sciences
Factors affecting deal valuation
Strategies to attract strategic buyers
- Konstantina Katcheves - SVP, BD, Alliance Management & Acquisitions, Teva Pharmaceuticals
- Matthias Müllenbeck - SVP, Head Global Business Development & Alliance Management, Merck KGaA
- Chris Sheldon - Senior Vice President, Head of Business Development, GSK
- Monika Vnuk - SVP, Global Partnering & Business Development, Sanofi
With the IPO boom of 2020 and 2021 leaving investors burnt by falling share prices there has been scepticism surrounding taking life science companies public. Join us as our panel discuss when and how to consider an IPO to provide the greatest chances of success in the public market.
IPO readiness and timing
Pros and cons of the European and US public markets
Post-IPO considerations and investor relations
SPAC opportunities and alternative listing routes
- Mike Griffiths - CEO, AOTI
The AI landscape continues to evolve, integration in life science startups is becoming commonplace. As artificial intelligence continues to promise revolutionary advances, investors and partners face critical questions about demonstrable value, investment priorities, and whether the AI boom has reached its peak. Join us as our experts discuss AI adoption, exploring both breakthrough potential and persistent challenges in this rapidly evolving field.
How can life science startups effectively prove the value of their AI technologies beyond the hype?
The value of being an AI forward life science company, has investor enthusiasm peaked?
The future of AI for strategic players, are big pharma and Tier 1 medtechs developing AI tools in-house or looking externally for innovation?
- Paul Ashley - Director, External Innovation, Data Science and Digital Health, Johnson & Johnson
- Joanna Soroka - Principal, Hitachi Ventures
The so called “valley of death” between early and late-stage funding continues to prove a critical risk to life science companies. With venture capital funds unable to support the entire industry on their own, alternative funding sources are on the rise. Learn more about the differences between traditional and novel funding sources and what is best for your company.
Structured financing options, royalty financing and venture debt
How private equity differs from traditional VC funding
Strategic partnerships and licensing deals
- Jonathan Brayman - Managing Director, Blackstone
- Sam Gray - Managing Partner, Apposite Capital
- Ari-Pekka Laitsaari - Life Science & Biotech, Equity and Growth Capital, European Investment Bank
- Bihe Chen - Operating Director, Limerston Capital
- Discussing the important role of family offices in supporting startups
- What unique advantages do family offices offer compared to traditional venture capital firms?
- Best practice/ strategies for approaching and working with family offices
- Laurent Pacheco - Managing Partner, Health Family Office Alliance
Recent reports have highlighted the evolving role of large strategics in powering innovation in life science. With a possible shift away from internal R&D, big pharma and tier 1 medtechs are looking for external innovation to drive growth in their business units. Join our panel of CVC leaders as they discuss their process and rationale for investment and strategies for getting in front of these global giants.
Strategic vs. financial investment approaches
CVC investment criteria and focus areas
Building successful CVC partnerships
- Louise Warme - Head, We Venture Capital
- Christian Schubert - VP & Head, AbbVie Ventures
The biotech M&A landscape presents unique challenges and opportunities that differ significantly from other sectors. With extended development timelines, complex IP considerations, and specialized regulatory hurdles, biotech founders need tailored strategies to maximize value and ensure their innovations reach their full potential.
In this masterclass session we will delve into:
- Understanding the Biotech M&A Landscape
- Current trends in biotech acquisitions and valuations
- Valuation Methodologies for Biotech Companies
- Deal Structuring for Biotech Startups
- Due Diligence Preparation
- Negotiation Strategies and Tactics
- Post-Merger Integration for Scientific Teams
Unlock the secrets of successful pharma-biotech partnerships in this intensive masterclass designed specifically for life science entrepreneurs. Learn from industry experts who understand the complex dynamics of strategic alliances that can accelerate your innovation from lab to market. The pharma partnering masterclass will delve into;
• Proven strategies for identifying and securing the right pharmaceutical partners
• Discuss practical frameworks for structuring deals that maximize value while protecting your intellectual property
• Demonstrate how early-stage pharma collaborations can significantly enhance your startup's validation and success rates
• Provide guidance on valuation approaches and negotiation techniques specific to life science partnerships
• Equip you with tools to leverage partnerships for accessing critical resources, expertise, and market channels
• Include interactive sessions with industry experts who have successfully navigated partnerships from both sides of the table
This intensive masterclass equips biotech founders and executives with essential strategies to successfully navigate the complex world of technology licensing. Learn how to transform your scientific breakthroughs into valuable commercial agreements that accelerate development while maximizing returns.
This masterclass will:
• Provide proven frameworks for protecting and leveraging your intellectual property across different licensing models
• Deliver expert insights on structuring optimal licensing deals specific to various biotech assets and development stages
• Equip you with practical negotiation tactics to secure favourable terms when dealing with larger pharmaceutical companies
• Demonstrate effective valuation methodologies to ensure fair compensation for your platform technologies and therapeutic candidates
• Guide you through critical legal considerations that can make or break biotech licensing agreements
• Include interactive sessions with industry veterans who have successfully executed transformative licensing deals
- Status of the US IPO market in comparison to the EU/UK – current state of the US IPO market and outlook for the coming year
- Pre-IPO readiness check – what do you need in place to ensure you are in the best position for your IPO
- Understanding investor expectation and your equity story and why it is key to success – fireside chat [attendees to be confirmed – we will be reaching out to our contacts to confirm]
- What to expect from the IPO process – a summary view of the key elements of the active phase of the transaction
- Key lessons learned from previous transactions – highlighting the known unknowns
- Post-IPO and beyond – understanding your requirements as a listed company
This comprehensive masterclass equips life science entrepreneurs with essential strategies to build, protect, and leverage intellectual property assets that drive company valuation and create sustainable competitive advantages in the rapidly evolving healthcare innovation landscape.
This masterclass will:
• Provide practical frameworks for developing a strategic IP portfolio that aligns with your business objectives and therapeutic focus
• Deliver expert guidance on patent strategies specific to various life science modalities including biologics, gene therapies, and digital health
• Equip you with effective approaches to navigate freedom-to-operate challenges and competitive IP landscapes
• Demonstrate how to leverage IP assets in fundraising, partnerships, and exit strategies to maximize company valuation
• Guide you through critical decisions on global filing strategies and cost-effective IP management for resource-constrained startups
• Include interactive sessions with experienced IP attorneys and life science executives who have successfully built valuable IP portfolios
Topic to be confirmed